Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani
Antimony, which was mainstay for treating fatal visceral leishmaniasis (VL), has been withdrawn from Indian Subcontinent for more than a decade now due to emergence of resistance. Despite this, recent clinical LD isolates remain unresponsive to antimony ( …